Off-label use of drugs in pain medicine and palliative care: An algorithm for the assessment of its safe and legal prescription

Pain Practice

Volumn 8, Issue 3, 2008, Pages 157-163

  Verhagen, Constans A H H V M ^a   Niezink, Anne G H ^a   Engels, Yvonne Y ^a   Hekster, Yechiel Y A ^a   Doornebal, Joan J ^a   Vissers, Kris C P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Algorithm; Chronic pain; Evaluation; Off label prescription; Palliative care

Indexed keywords

ANALGESIC AGENT;

ALGORITHM; ARTICLE; CHRONIC PAIN; CLINICAL PRACTICE; DRUG ADMINISTRATION ROUTE; DRUG COST; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; DRUG TREATMENT FAILURE; HEALTH INSURANCE; HUMAN; LEGAL ASPECT; OFF LABEL DRUG USE; OPTIMAL DRUG DOSE; PALLIATIVE THERAPY; PATIENT SAFETY; PHYSICIAN; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; SKIN IRRITATION; TREATMENT OUTCOME;

ALGORITHMS; ANALGESIA; DECISION TREES; DRUG APPROVAL; DRUG LABELING; DRUG THERAPY; HUMANS; INTERDISCIPLINARY COMMUNICATION; LEGISLATION, DRUG; PAIN; PALLIATIVE CARE; PHARMACY AND THERAPEUTICS COMMITTEE; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG;

EID: 43449091617     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2008.00189.x     Document Type: Article

References (11)

1. FDA. The history of drug regulation in the United States. US Food and Drug Administration. http://www.fda.gov/centennial/history/history/html.
2. Novak E, Allen PJ. Prescribing medications in pediatrics: Concerns regarding FDA approval and pharmacokinetics. Pediatr Nurs. 2007;33:64-70.
3. Vitiello B, Jensen PS. Medication development and testing in children and adolescents. Current problems, future directions. Arch General Psychiatry. 1997;54:871-876.
4. Brandt HE, Deliens L, Ooms ME, et al. Symptoms, signs, problems, and diseases of terminally ill nursing home patients: A nationwide observational study in the Netherlands. Arch Intern Med. 2005;165:314-320.
5. Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: A prospective study. Acta Paediatr. 1999;88:965-968.
6. Atkinson CV, Kirkham SR. Unlicensed uses for medication in a palliative care unit. Palliat Med. 1999;13:145-152.
7. Todd J, Davies A. Use of unlicensed medication in palliative medicine. Palliat Med. 1999;13:446.
8. Ansani N, Branch R, Fedutes-Henderson B, et al. United States medical practice summary: Innovative off-label medication use. Am J Med Qual. 2006;21:246-254.
9. Conroy S. Unlicensed and off-label drug use: Issues and recommendations. Paediatr Drugs. 2002;4:353-359.
10. Ansani N, Sirio C, Smitherman T, et al. Designing a strategy to promote safe, innovative off-label use of medications. Am J Med Qual. 2006;21:255-261.
11. Gazarian M, Kelly M, McPhee JR, et al. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006;185:544-548.